Intergalactic Therapeutics really is shooting for the stars in its audacious mission to develop a non-viral gene therapy that doesn't require cells in the manufacturing process and can be re-dosed. The biotech's incubator, Apple Tree Partners, is pumping $75 million of rocket fuel into the biotech with a clinical telescope pointed toward ophthalmology, oncology and other potential disease targets.